

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		<b>Application Number</b>	10/657,363
		<b>Filing Date</b>	September 8, 2003
		<b>First Named Inventor</b>	Young et al.
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Hill, Myron G.
		<b>Attorney Docket No.</b>	10271-159-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	J01	4,517,304	05/14/1985	Stott et al.	
	J02	4,526,938	07/2/1985	Churchhill et al.	
	J03	4,659,563	04/21/1987	Dobkin	
	J04	4,717,766	01/05/1988	Dobkin	
	J05	4,760,026	07/26/1988	Lennox et al.	
	J06	4,853,326	08/01/1989	Quash et al.	
	J07	4,917,893	04/17/1990	Okada et al.	
	J08	5,071,758	12/10/1991	Stott et al.	
	J09	5,128,326	07/07/1992	Balazs et al.	
	J10	5,137,804	08/11/1992	Greene et al.	
	J11	5,149,650	09/22/1992	Wertz et al.	
	J12	5,183,657	02/2/1993	Buurman	
	J13	5,194,595	03/16/1993	Wathen	
	J14	5,219,996	06/15/1993	Bodmer et al.	
	J15	5,223,254	06/29/1993	Paradiso et al.	
	J16	5,240,694	08/31/1993	Gwaltney, Jr.	
	J17	5,271,927	12/21/1993	Parker et al.	
	J18	5,279,935	01/18/1994	Nycz	
	J19	5,288,630	02/22/1994	Wathen	
	J20	5,332,567	07/26/1994	Goldenberg	
	J21	5,332,805	07/26/1994	Carey et al.	
	J22	5,340,926	08/23/1994	Lowe et al.	
	J23	5,354,554	10/11/1994	Rhind	
	J24	5,391,478	02/21/1995	Greene et al.	
	J25	5,411,749	05/2/1995	Mayo et al.	
	J26	5,412,077	05/2/1995	Siber et al.	

LAI-3012585v2

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	Young et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159.999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	J27	5,418,136	05/23/1995	Miller et al.	
	J28	5,422,097	06/06/1995	Gwaltney Jr.	
	J29	5,424,189	06/13/1995	Oberst et al.	
	J30	5,468,606	11/21/1995	Bogart et al.	
	J31	5,470,736	11/28/1995	Verma et al.	
	J32	5,476,997	12/19/1995	Kaneshima et al.	
	J33	5,484,893	01/16/1996	Parker et al.	
	J34	5,506,209	04/09/1996	Mukerji et al.	
	J35	5,518,725	05/21/1996	Daynes et al.	
	J36	5,530,102	06/25/1996	Gristina et al.	
	J37	5,538,733	07/23/1996	Emery et al.	
	J38	5,538,952	07/23/1996	Mukerji et al.	
	J39	5,624,821	04/29/1997	Winter	
	J40	5,648,260	07/15/1997	Winter	
	J41	5,679,377	10/21/1997	Bernstein et al.	
	J42	5,855,913	01/05/1999	Hanes et al.	
	J43	5,874,064	02/23/1999	Edwards et al.	
	J44	5,912,015	06/15/1999	Bernstein et al.	
	J45	5,916,597	06/29/1999	Lee et al.	
	J46	5,934,272	08/10/1999	Lloyd et al.	
	J47	5,985,309	11/16/1999	Edwards et al.	
	J48	5,985,320	11/16/1999	Edwards et al.	
	J49	5,989,463	11/23/1999	Tracy et al.	
	J50	6,019,968	02/01/2000	Platz et al.	
	J51	6,121,022	09/19/2000	Presta	
	J52	6,194,551	02/27/2001	Idusogie	

LAI-3012585v2

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		<b>Application Number</b>	10/657,363
		<b>Filing Date</b>	September 8, 2003
		<b>First Named Inventor</b>	Young et al.
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Hill, Myron G.
		<b>Attorney Docket No.</b>	10271-159-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	J53	6,277,375	08/21/2001	Ward	
	J54	6,519,948	02/18/2003	Zorn	
	J55	6,528,624	03/04/2003	Idusogic	
	J56	6,538,124	03/25/2003	Idusogic	
	J57	6,565,888	05/20/2003	Tracy et al.	
	J58	6,737,056	05/18/2004	Presta	
	J59	7,083,784	08/01/2006	Dall'Acqua	
	J60	7,416,726	08/26/2008	Ravetch	
	J61	2004-0131609	07/08/2004	Young et al.	
	J62	2004-0002587	01/01/2004	Watkins	
	J63	US 2006-0099220	05/11/2006	Tous et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	K01	AU 2002219944	02/21/2008	MedImmune, Inc.		
	K02	EP 0413622	02/20/1991	Rhone Poulen Rorer SA		
	K03	EP 0451216	01/24/1996	Protein Design Labs Inc		
	K04	EP 0682040	11/15/1995	Protein Design Labs Inc		
	K05	WO 00/42072	07/20/2000	Genentech Inc.		
	K06	WO 01/58957	08/16/2001	Lexigen Pharm. Corp.		
	K07	WO 03/054213	07/03/2003	Genentech Inc.		
	K08	WO 04/010935	02/05/2004	MedImmune		
	K09	WO 04/029207	04/08/2004	Xencor et al.		
	K10	WO 04/035752	04/29/2004	Protein Design Labs. Inc.		

LA1-3012585v2

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		<b>Application Number</b>	10/657,363
		<b>Filing Date</b>	September 8, 2003
		<b>First Named Inventor</b>	Young et al.
		<b>Art Unit</b>	1648
		<b>Examiner Name</b>	Hill, Myron G.
		<b>Attorney Docket No.</b>	10271-159-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	K11	WO 06/034292	03/30/2006	MedImmune		
	K12	WO 90/07861	07/26/1990	Protein Design Labs, Inc.		
	K13	WO 91/05548	05/02/1991	Pitman-Moore Inc.		
	K14	WO 93/05796	04/01/1993	The Scripps Research Institute		
	K15	WO 93/15200	08/05/1993	Rhone Poulenc Rorer SA		
	K16	WO 93/19197	09/30/1993	Immunet		
	K17	WO 93/20210	10/14/1993	Scotgen Limited		
	K18	WO 95/04081	02/09/1995	Oravax, Inc.		
	K19	WO 96/20698	07/11/1996	The Board of Regents acting for and on behalf of The University Of Michigan		
	K20	WO 97/32572	09/12/1997	The Penn State Research Foundation of Massachusetts Institute Of Technology		
	K21	WO 97/34631	09/25/1997	Board Of Regents, The University Of Texas System Ward		
	K22	WO 97/44013	11/27/1997	Massachusetts Institute Of Technology The Penn State Research Foundation		
	K23	WO 98/23289	06/04/1998	The General Hospital Corp.		
	K24	WO 98/31346	07/23/1998	Massachusetts Institute Of Technology; The Penn State Research Foundation		
	K25	WO 99/15154	04/01/1999	Alkermes Controlled Therapeutics, Inc.		
	K26	WO 99/20253	04/29/1999	Bioglan Therapeutics AB		
	K27	WO 99/51642	10/14/1999	Genentech Inc.		
	K28	WO 99/66903	12/29/1999	Advanced Inhalation Research, Inc.		
	K29	WO 07/002543	01/04/2007	MedImmune		
	K30	WO 09/003019	12/31/2008	MedImmune		

LAI-3012585v2

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/	

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	Young et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
L01	Adams et al., 1998. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies, Cancer Res. 58(3):485-90.		
L02	American Academy of Pediatrics Committee on Infectious Diseases: Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection. Pediatrics. 1993 Sep;92(3):501-4.		
L03	Bennett et al., 2007. Immunopathogenesis of Respiratory Syncytial Virus Bronchiolitis, JID, 195:1532-1540.		
L04	Bentley and Rabbits, 1980. Human immunoglobulin variable region genes-- DNA Sequences of Two V Kappa Genes and a Pseudogene, Nature 288: 730-733.		
L05	Boulianne et al., 1984. Production of functional chimaeric mouse/human antibody, Nature 312(5995):643-646.		
L06	Carson and Freimark, 1986. Human lymphocyte hybridomas and monoclonal antibodies, Adv. Immunol. 38:275-311.		
L07	Chothia et al., 1998. Structural determinants in the sequences of immunoglobulin variable domain. J Mol Biol. 278(2):457-79.		
L08	Cleek et al., 1997. Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application, Pro. Int'l Symp. Control. Rel. Bioact. Mater. 24: 853-854.		
L09	Colman 1994. Effects of amino acid sequence changes on antibody-antigen interactions; Res Immunol. 145(1):33-6.		
L10	Crowe et al., 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice, Proc. Natl. Acad. Sci. USA, 91:1386-1390.		
L11	DeVincenzo, 2005. Factors Predicting Childhood Respiratory Syncytial Virus Severity. What They Indicate About Pathogenesis. The Pediatric Infectious Disease Journal, 24(11):S177-S183.		
L12	Downham et al., 1976. Breast-feeding protects against respiratory syncytial virus infections. Br Med J. 2(6030):274-6.		
L13	Edelman et al., 1969. The Covalent Structure of an Entire gammaG Immunoglobulin Molecule. PNAS 63:78-85.		
L14	Fields et al., 1990, Fields Virology, 2nd Ed., Vol. I, Raven Press, NY p. 1045-1072.		
L15	Garvis and Gray, 1980. Outbreak of Respiratory Syncytial Virus Infection in the Elderly, Br Med J. 281(6250):1253-4.		
L16	Gillies et al., 1989. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol Methods. 125:191-202.		
L17	Hemming et al., 1988. Topically Administered Immunoglobulin Reduces Pulmonary Respiratory Syncytial Virus Shedding in Owl Monkeys. Antimicrobial Agents and Chemotherapy, 32(8):1269-1270.		
L18	Howard et al., 1989. Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits, J Neurosurg. 71(1):105-12.		
L19	Hudson and Souriau, 2003. Engineered Antibodies. Nature Medicine 9(1):129-34.		
L20	Ichiyoshi et al., 1995. A human anti-insulin IgG autoantibody apparently arises through clonal selection from an insulin-specific "germ-line" natural antibody template. Analysis by V gene segment reassortment and site-directed mutagenesis, J. Immunol. 154(1):226-38.		
L21	Jackson et al., 1998. Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives, Br. J. Cancer 78(2):181-8.		

LAI-3012585v2

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	Young et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	L22	Johnson et al., 1987. The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins, Proc Natl Acad Sci U S A. 84(16):5625-9.	
	L23	Johnson et al., 1991. Development of humanized monoclonal antibodies which neutralize respiratory syncytial virus, J. Cellular Biochem. Suppl. 15E. P.120, Abstract No. 108.	
	L24	Kapikian et al., 1969. An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine, Am J Epidemiol. 89(4):405-21.	
	L25	Levy et al., 1985. Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-release Diphosphonate, Science. 228(4696):190-2.	
	L26	Liu et al., 1987. Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells, Gene 54(1):33-40.	
	L27	Maynard et al., 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity, Nat. Biotechnol. 20(6):597-601.	
	L28	Mejias et al., 2005. Respiratory syncytial virus infections: Old challenges and new opportunities, Ped. Infect. Dis. J. 24: S189-S197.	
	L29	Mejias et al., 2005. Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency, Antimicrobial Agents and Chemotherapy Vol. 49, No. 11: 4700-4707.	
	L30	Morrison et al., 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA 81(21):6851-6855.	
	L31	Morrison et al., 1985. Transfectedomas provide novel chimeric antibodies, Science 229(4719):1202-1207.	
	L32	Murphy et al., 1994. An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines, Virus Res. 32(1):13-36.	
	L33	Ning et al., 1996. Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained Release Gel, Radiotherapy and Oncology 39: 179-89.	
	L34	Ogra et al., 1988. Respiratory Syncytial Virus Infection and the Immunocompromised Host, Pediatr Infect Dis J. 1988 Apr;(74):246-9.	
	L35	Orkin and Motulsky, Report and recommendations of the panel to assess the NIH investment in research on gene therapy, available from <a href="http://www.nih.gov/news/panelrep.html">http://www.nih.gov/news/panelrep.html</a> (1995).	
	L36	Padlan, 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, Mol. Immunol. 28(4/5):489-498.	
	L37	Pohl et al., 1992. Respiratory Syncytial Virus Infections in Pediatric Liver Transplant Recipients, J Infect Dis. 165(1):166-9.	
	L38	Press et al., 1970. The Amino Acid Sequences of the Fd Fragments of Two Human Gamma-I Heavy chains, Biochem J. 117(4):641-60.	
	L39	Prince et al., 1987. Effectiveness of Topically Administered Neutralizing Antibodies in Experimental Immunotherapy of Respiratory Syncytial Virus Infection in Cotton Rats, Journal of Virology, 61(6):1851-1854.	
	L40	Riechmann et al., 1988. Reshaping human antibodies for therapy. Nature. 332(6162):323-7.	
	L41	Ruuskanen et al., 1993. Respiratory syncytial virus, Curr Probl Pediatr. 23(2):50-79.	

LAI-3012585v2

EXAMINER SIGNATURE	DATE CONSIDERED
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

<b>Application Number</b>	10/657,363
<b>Filing Date</b>	September 8, 2003
<b>First Named Inventor</b>	Young et al.
<b>Art Unit</b>	1648
<b>Examiner Name</b>	Hill, Myron G.
<b>Attorney Docket No.</b>	10271-159-999

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
L42	Sauder et al., 1989. A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery. <i>N Engl J Med.</i> 321(9):574-9.		
L43	Scott et al., 1985. Cellular reactivity to respiratory syncytial virus in human colostrum and breast milk. <i>J Med Virol.</i> 17(1):83-93.		
L44	Sefton, 1987. Implantable Pumps, CRC Crit. Rev. Biomed. Eng. 14:201-240.		
L45	Sevier et al., 1981. Monoclonal antibodies in clinical immunology. <i>Clin Chem.</i> 27(11):1797-806.		
L46	Song et al., 1995. Antibody Mediated Lung Targeting of Long-Circulating Emulsions, PDA Journal of Pharmaceutical Science & Technology 50: 372-77.		
L47	Studnicka et al., 1994. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. <i>Protein Eng.</i> 7:805-814.		
L48	Taylor et al., 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. <i>Immunology.</i> 52(1):137-42.		
L49	Taylor et al., 1992. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. <i>J Gen Virol.</i> 73 (Pt 9):2217-23.		
L50	Van Wyke Coelingh et al., 1985. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. <i>Virology</i> 143(2):569-582.		
L51	Verma et al., 1997. Gene therapy - promises, problems and prospects. <i>Nature</i> 389:239-242.		
L52	Wald et al., 1988. In re ribavirin: a case of premature adjudication? <i>J. Pediatr.</i> 112(1):154-158.		
L53	Walsh et al., 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. <i>Infect Immun.</i> 43(2):756-8.		
L54	Watkins et al., 1997. Determination of the relative affinities of antibody fragments expressed in Escherichia coli by enzyme-linked immunosorbent assay. <i>Anal Biochem.</i> 253(1):37-45.		
L55	Wright et al., 1982. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. <i>Infect. Immun.</i> 37(1):397-400.		
L56	Wu et al., 2008. Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab in Human Antibody Therapeutics for Viral Disease. Current Topics in Microbiology and Immunology 317. Springer-Verlag Berlin Heidelberg, p. 103-123.		
L57	U.S. Serial No. 10/900,230 (U.S. Publ. No. 2005/0002926) - Interview Summary dated 03/27/2009		
L58	U.S. Serial No. 09/796,848 (U.S. Publ. No. 2002/009189) - Office Action dated 01/22/2009		

/Myron Hill/

06/21/2009

LAJ-3012585v2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

EXAMINER  
SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/